Cingulate Inc. — Board/Management Information 2025

Jan 24, 2025

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 17, 2025

CINGULATE INC.

(Exact name of registrant as specified in its charter)

Delaware	001-40874	86-3825535
(State
or other jurisdiction	(Commission	(IRS
Employer
of
incorporation)	File
Number)	Identification
No.)

1901 W. 47 th Place Kansas City, KS 66205 (Address of principal executive offices) (Zip Code) (913) 942-2300

(Registrant’s telephone number, including area code)

_____________
(Former
name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $0.0001 per share | CING | The
Nasdaq Stock Market LLC (Nasdaq
Capital Market) |
| Warrants,
exercisable for one share of common stock | CINGW | The
Nasdaq Stock Market LLC (Nasdaq
Capital Market) |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 17, 2025, the Compensation Committee of the Board of Directors of Cingulate Inc. (the “Company”) approved an amendment, effective January 1, 2025 (the “Amendment”), to the Employment Agreement between Matthew N. Brams, Executive Vice President and Chief Medical Officer, and Cingulate Therapeutics LLC , effective September 23, 2021, as amended. Pursuant to the Amendment, Mr. Brams will be entitled to receive an annual base salary of $165,000 and will no longer be entitled to receive quarterly equity grants. Mr. Brams will continue to be entitled to receive an annual equity grant as determined by the Compensation Committee.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

| Exhibit
No. | Description |
| --- | --- |
| 10.1 | Amendment to Employment Agreement, effective January 1, 2025, between Cingulate Therapeutics, LLC and Matthew N. Brams |
| 104 | Cover
Page Interactive Data File (embedded within the Inline XBRL document) |

Field: Page; Sequence: 2

Field: /Page

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| CINGULATE
INC. — By: | /s/
Shane J. Schaffer |
| --- | --- |
| Name: | Shane
J. Schaffer |
| Title: | Chief
Executive Officer |

Field: Page; Sequence: 3; Options: Last

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kUFuwjAQRU/AHUZRlxHYrthkRyNAVaEgQJStCZPWIvFEY0PhSL1lHaeILlrLkjWaef//kZMkTaY0MRUy7J5WM9hg3VTaI6ywREZbYJjIn18yCO8K343zrK2P5Q3MKTAYmGFfDXVoxNGzcXjIQMiBehyoIUiRKQmjedJr+znZ0hzQeqMr0PYAS6aGDXrN105hoy9kqb5Gqy2yM2QzkH3Rtb9ACanglc76k/joYDbLk14aTy+ZMp2aMDW+eLQtCeMK62DnOvp+Y5ri5DzV2Zvmdjk3viAXxul9hRPihcX1h2ZclGHRmuzaU3GcY71HDqgUSkkx+kl1U0gB7xpQEgNZBNfKAJVQRCFwrdIfOX75LDVvdXVC0RdCyCVyjPKPe8dBBFNoNMO5ZeGho6EJnxUz3Dy/AToZmxc=